These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
624 related articles for article (PubMed ID: 17387236)
1. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill. Wester JP; Leyte A; Oudemans-van Straaten HM; Bosman RJ; van der Spoel JI; Haak EA; Porcelijn L; Zandstra DF Neth J Med; 2007 Mar; 65(3):101-8. PubMed ID: 17387236 [TBL] [Abstract][Full Text] [Related]
2. Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients. Cegarra-Sanmartín V; González-Rodríguez R; Paniagua-Iglesias P; Santamaría-Ortiz A; Cueva LF; Galán-Serrano J; Moral-García MV J Cardiothorac Vasc Anesth; 2014 Aug; 28(4):1008-12. PubMed ID: 24439171 [TBL] [Abstract][Full Text] [Related]
3. Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin. ten Berg MJ; van den Bemt PM; Huisman A; Schobben AF; Egberts TC; van Solinge WW Ann Pharmacother; 2009 Sep; 43(9):1405-12. PubMed ID: 19690229 [TBL] [Abstract][Full Text] [Related]
4. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Efird LE; Kockler DR Ann Pharmacother; 2006; 40(7-8):1383-7. PubMed ID: 16788093 [TBL] [Abstract][Full Text] [Related]
5. Anticoagulation with fondaparinux for hemodiafiltration in patients with heparin-induced thrombocytopenia: dose-finding study and safety evaluation. Mahieu E; Claes K; Jacquemin M; Evenepoel P; Op De Beek K; Bogaert AM; Kuypers D; Verhamme P; Meijers B Artif Organs; 2013 May; 37(5):482-7. PubMed ID: 23461610 [TBL] [Abstract][Full Text] [Related]
6. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Lobo B; Finch C; Howard A; Minhas S Thromb Haemost; 2008 Jan; 99(1):208-14. PubMed ID: 18217156 [TBL] [Abstract][Full Text] [Related]
7. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience. Grouzi E; Kyriakou E; Panagou I; Spiliotopoulou I Clin Appl Thromb Hemost; 2010 Dec; 16(6):663-7. PubMed ID: 19825921 [TBL] [Abstract][Full Text] [Related]
8. Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues. Blackmer AB; Oertel MD; Valgus JM Ann Pharmacother; 2009 Oct; 43(10):1636-46. PubMed ID: 19737996 [TBL] [Abstract][Full Text] [Related]
9. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226 [TBL] [Abstract][Full Text] [Related]
10. The HIT treatment in a cardiac surgery patient. Anna N; Boyan T; Kader MA; Catherine M; Matthias K Int J Cardiol; 2010 Oct; 144(3):405-7. PubMed ID: 19324432 [TBL] [Abstract][Full Text] [Related]
11. Heparin-induced thrombocytopenia in intensive care patients. Selleng K; Selleng S; Greinacher A Semin Thromb Hemost; 2008 Jul; 34(5):425-38. PubMed ID: 18956282 [TBL] [Abstract][Full Text] [Related]
12. Outcome of postoperative critically ill patients with heparin-induced thrombocytopenia: an observational retrospective case-control study. Gettings EM; Brush KA; Van Cott EM; Hurford WE Crit Care; 2006; 10(6):R161. PubMed ID: 17109753 [TBL] [Abstract][Full Text] [Related]
13. Fondaparinux cross-reacts with heparin antibodies in vitro in a patient with fondaparinux-related thrombocytopenia. Pistulli R; Oberle V; Figulla HR; Yilmaz A; Pfeifer R Blood Coagul Fibrinolysis; 2011 Jan; 22(1):76-8. PubMed ID: 21076279 [TBL] [Abstract][Full Text] [Related]
14. Heparin-induced thrombocytopenia: recent experience in a large teaching hospital. Sturtevant JM; Pillans PI; Mackenzie F; Gibbs HH Intern Med J; 2006 Jul; 36(7):431-6. PubMed ID: 16780449 [TBL] [Abstract][Full Text] [Related]
15. The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. Crowther MA; Cook DJ; Albert M; Williamson D; Meade M; Granton J; Skrobik Y; Langevin S; Mehta S; Hebert P; Guyatt GH; Geerts W; Rabbat C; Douketis J; Zytaruk N; Sheppard J; Greinacher A; Warkentin TE; J Crit Care; 2010 Jun; 25(2):287-93. PubMed ID: 20149589 [TBL] [Abstract][Full Text] [Related]
16. Application, tolerance and safety of fondaparinux therapy in a German hospital: a prospective single-centre experience. Schindewolf M; Scheuermann J; Kroll H; Marzi I; Kaufmann R; Boehncke WH; Ludwig RJ; Lindhoff-Last E Thromb Res; 2012 Jan; 129(1):17-21. PubMed ID: 21741076 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Fondaparinux in Patients With Suspected Heparin-Induced Thrombocytopenia. Snodgrass MN; Shields J; Rai H Clin Appl Thromb Hemost; 2016 Nov; 22(8):712-717. PubMed ID: 27179015 [TBL] [Abstract][Full Text] [Related]
18. Fondaparinux: does it cause HIT? Can it treat HIT? Warkentin TE Expert Rev Hematol; 2010 Oct; 3(5):567-81. PubMed ID: 21083474 [TBL] [Abstract][Full Text] [Related]
19. Fondaparinux as a treatment option for heparin-induced thrombocytopenia. Papadopoulos S; Flynn JD; Lewis DA Pharmacotherapy; 2007 Jun; 27(6):921-6. PubMed ID: 17542773 [TBL] [Abstract][Full Text] [Related]
20. Fondaparinux in a critically Ill patient with heparin-induced thrombocytopenia: A case report. He Y; He H; Liu D; Long Y; Su L; Cheng W Medicine (Baltimore); 2018 Sep; 97(37):e12236. PubMed ID: 30212955 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]